Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022
May 25 2022 - 1:00PM
Oxurion Announces Results of the Extraordinary Shareholders’
Meeting held on 24 May 2022
Leuven,
Belgium, Boston, MA, US –
May 25,
2022 –
07.00
PM CET
– Oxurion NV (Euronext Brussels: OXUR) (the
“Company” or “Oxurion”), a biopharmaceutical company developing
next generation standard of care ophthalmic therapies, with
clinical stage assets in vascular retinal disorders, held its
extraordinary shareholders' meeting on May 24, 2022. The
shareholders approved all items on the agenda of the extraordinary
shareholders' meeting.
All documents pertaining to this extraordinary
shareholders’ meeting, can be consulted on Oxurion’s website
Oxurion/shareholders.
About Oxurion Oxurion (Euronext
Brussels: OXUR) is a biopharmaceutical company developing next
generation standard of care ophthalmic therapies, which are
designed to improve and better preserve vision in patients with
retinal disorders including diabetic macular edema (DME), the
leading cause of vision loss in working-age people, as well as
other conditions. Oxurion intends to play an important role in the
treatment of retinal disorders, including the successful
development of THR-149, its novel therapeutic for the treatment of
DME. THR-149 is a potent plasma kallikrein inhibitor being
developed as a potential new standard of care for the up to 50% of
DME patients showing suboptimal response to anti-VEGF therapy.
Oxurion is headquartered in Leuven, Belgium, with corporate
operations in Boston, MA. More information is available at
www.oxurion.com.Important information about forward-looking
statementsCertain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michaël DillenChief Business
OfficerTel: +32 479 783 583michael.dillen@oxurion.com |
US Conway CommunicationsBeth
Kurthbkurth@conwaycommsir.com ICR WestwickeChristopher
BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com |
- PR Oxurion NV_Results EGM_(ENG)_20220525
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Sep 2023 to Sep 2024